Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Holdings Raised by Vanguard Group Inc.

Vanguard Group Inc. grew its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 2.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,710,307 shares of the company’s stock after purchasing an additional 36,785 shares during the period. Vanguard Group Inc. owned about 3.12% of Olema Pharmaceuticals worth $21,122,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Royal Bank of Canada lifted its holdings in shares of Olema Pharmaceuticals by 682.4% during the second quarter. Royal Bank of Canada now owns 2,801 shares of the company’s stock valued at $25,000 after purchasing an additional 2,443 shares during the last quarter. Jane Street Group LLC acquired a new position in Olema Pharmaceuticals during the fourth quarter valued at $28,000. Balyasny Asset Management LLC acquired a new position in Olema Pharmaceuticals during the third quarter valued at $33,000. Virtu Financial LLC acquired a new position in Olema Pharmaceuticals during the fourth quarter valued at $33,000. Finally, Citigroup Inc. acquired a new position in Olema Pharmaceuticals during the first quarter valued at $34,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Olema Pharmaceuticals Price Performance

Shares of OLMA stock opened at $10.86 on Friday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $3.53 and a fifty-two week high of $17.79. The stock’s 50-day moving average is $12.90 and its two-hundred day moving average is $13.02. The firm has a market cap of $607.29 million, a P/E ratio of -5.03 and a beta of 2.10.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, March 11th. The company reported ($0.49) EPS for the quarter, meeting analysts’ consensus estimates of ($0.49). As a group, research analysts expect that Olema Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Analysts Set New Price Targets

OLMA has been the topic of several recent analyst reports. Citigroup initiated coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a “buy” rating and a $20.00 price target on the stock. Capital One Financial reissued an “overweight” rating on shares of Olema Pharmaceuticals in a research report on Thursday, February 22nd. Finally, The Goldman Sachs Group began coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a “buy” rating and a $24.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $21.43.

Insider Activity

In other news, Director Cyrus Harmon sold 25,000 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00. Following the transaction, the director now owns 846,283 shares of the company’s stock, valued at approximately $10,502,372.03. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have sold 70,000 shares of company stock valued at $835,400. Insiders own 23.50% of the company’s stock.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.